临床儿科杂志
臨床兒科雜誌
림상인과잡지
2014年
5期
401-404
,共4页
非霍奇金淋巴瘤%B细胞%儿童%青少年
非霍奇金淋巴瘤%B細胞%兒童%青少年
비곽기금림파류%B세포%인동%청소년
non-Hodgkin lymphoma%B-cell%children%adolescent
成熟B细胞非霍奇金淋巴瘤（B-NHL）占儿童和青少年非霍奇金淋巴瘤的55%~60%。以伯基特淋巴瘤和弥漫大B细胞淋巴瘤最为常见。短疗程的多药联合强化疗可使儿童和青少年B-NHL的总体生存率达80%以上。影响B-NHL预后的相关因素包括，骨髓或中枢神经系统受累与否、血清乳酸脱氢酶水平以及化疗后患儿的动态反应。在分子生物学水平上寻找新的危险因子，寻找新的治疗方法以减少治疗相关不良反应是未来临床研究的重点。文章就目前儿童和青少年B-NHL临床诊治要点进行回顾分析。
成熟B細胞非霍奇金淋巴瘤（B-NHL）佔兒童和青少年非霍奇金淋巴瘤的55%~60%。以伯基特淋巴瘤和瀰漫大B細胞淋巴瘤最為常見。短療程的多藥聯閤彊化療可使兒童和青少年B-NHL的總體生存率達80%以上。影響B-NHL預後的相關因素包括，骨髓或中樞神經繫統受纍與否、血清乳痠脫氫酶水平以及化療後患兒的動態反應。在分子生物學水平上尋找新的危險因子，尋找新的治療方法以減少治療相關不良反應是未來臨床研究的重點。文章就目前兒童和青少年B-NHL臨床診治要點進行迴顧分析。
성숙B세포비곽기금림파류（B-NHL）점인동화청소년비곽기금림파류적55%~60%。이백기특림파류화미만대B세포림파류최위상견。단료정적다약연합강화료가사인동화청소년B-NHL적총체생존솔체80%이상。영향B-NHL예후적상관인소포괄，골수혹중추신경계통수루여부、혈청유산탈경매수평이급화료후환인적동태반응。재분자생물학수평상심조신적위험인자，심조신적치료방법이감소치료상관불량반응시미래림상연구적중점。문장취목전인동화청소년B-NHL림상진치요점진행회고분석。
Mature B-cell non-Hodgkin lymphoma (B-NHL) represents about 55%-60%of all NHL cases in children and adolescents. Burkitt lymphoma and diffuse large B-cell lymphoma are the most common subtypes. Current combination chemo-therapy regimen succeeds in overall survival rates of more than 80%. Risk factors for the prognosis of childhood and adolescent B-NHL include bone marrow and central nervous system involvement, serum lactate dehydrogenase level and kinetics of re-sponse to therapy. Future strategies should include further understanding of the genetic alternation of B-NHL and utilization of novel target therapies to decrease treatment-related toxicity. We performed a retrospective analysis on the treatment of child and adolescent mature B-cell lymphoma.
